Denmark has decided to exclude Johnson & Johnson's COVID-19 product from its vaccination program following reports of rare blood clots in recipients.
The European Union's drug regulator last month said blood clots confirmed after inoculation with the Johnson & Johnson vaccine should be listed as a "very rare side effect." It also said the benefit of the vaccine in preventing COVID-19 outweighs the risk.
The Danish Health Authority said on Monday it independently examined the matter, and that it will halt the plan to use Johnson & Johnson vaccine.
It says that the epidemic in the country is currently under control, and that the vaccination rollout is progressing satisfactorily with other available vaccines.
Denmark had already stopped using AstraZeneca's COVID-19 vaccine, citing similar concerns.
The Danish authority said the removal of the Johnson & Johnson vaccine could result in a delay of up to four weeks in its vaccination program.